Long time holder, first time poster on this stock.
The 4C was pretty much right on the money from my perspective. Extrapolate out with some back-of-envelope assumptions, Q-on-Q growth of 15% (conservative with Menicon yet to contribute meaningfully), costs increasing at 3%, and you reach CF+ in the first quarter 2023, with being able to spend roughly up to $7M of the cash balance on clinical trials and development.
Good situation to be in.
The fundamentals of this company are attractive IMO:
Distinctive and protected tech
Huge market opportunity
Established distribution in multiple countries already in place
Revenue consistently coming in the door
Sensible management - COVID response was first class
Multinational partner, with the potential of more partersnhips to come (J&J)
Strong support from Thorney - they seem willing to throw money at this whenever it is needed.
Extremely attractive as an acquistion for a larger player should management see the right deal on the table.
Share price is annoying, and the consolidation hasn't (yet) delivered any benefit, but this was always a position that was going to require patience.
I'll be adding to my position at these levels (or lower as weak hands get tired of waiting) when I can.
VTI Price at posting:
95.0¢ Sentiment: Buy Disclosure: Held
